Compare IQIYI Inc - ADR (IQ) vs Eli Lilly And Co (LLY) Price & Performance

iQIYI (IQ) trades at $1.015, up 0.5% with neutral technical signals. The company reported Q2 2026 revenue of $6.3 billion (up 1% sequentially) but posted a net loss of -$206 million in 2025. Valuation metrics show mixed signals with low P/S (0.25) and P/B (0.52) ratios but elevated P/E (144.05) due to negative earnings. Recent news highlights AI-driven content expansion with over 350 new titles announced for 2026-2027.

Investment outlook remains cautious despite analyst consensus leaning bullish (50% buy ratings). The streaming business faces revenue pressure with 2026 projections showing -3.22% net margin, though AI content initiatives could improve cost structure. Key risks include Chinese regulatory environment and streaming competition. Institutional sentiment appears divided given mixed technical indicators and fundamental challenges.

Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.

Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.